Join our daily newsletter At The Bell to receive exclusive market insights
- Oncosil Medical (OSL) has been granted Hong Kong regulatory approval for its namesake device as a treatment for pancreatic cancer
- Oncosil is a targeted radioactive isotope, implanted into locally advanced pancreatic tumours via an endoscopic ultrasound
- The approval gives the company access to a key market in its ASEAN commercialisation strategy and follows approvals from Singapore and Malaysia
- Oncosil is also awaiting the outcome of its application to the Australian regulator
- Shares closed 4.3 per cent higher at 9.8 cents
Oncosil Medical (OSL) has been granted Hong Kong regulatory approval for its namesake device as a treatment for pancreatic cancer.
Oncosil is a targeted radioactive isotope and works by being implanted directly into the locally advanced pancreatic tumour via an endoscopic ultrasound.
The approval from the Medical Device Division of the Department of Health allows the company to market and sell the device in Hong Kong.
Oncosil views the market as strategic due to the small number of hospitals treating the disease and the elevated healthcare spending per capita relative to other countries in the region.
Oncosil also described the approval as a key step in its ASEAN commercialisation strategy. It follows approvals from regulators in Singapore and Malaysia last year.
The company is awaiting the outcome of its application to the Australian regulator, the Therapeutic Goods Administration.
Shares closed 4.3 per cent higher at 9.8 cents.
